As the existing comprehensive recommendations for cancer control policies are mostly derived from Western countries, non-Western nations should strive to tailor their own policies based on their local lifestyle, burden of cancer and characteristics of the local healthcare system.
Newer molecular tests for high-risk human papillomavirus (hrHPV) may provide a cost-effective means for cervical cancer screening for low-to-middle income countries (LMICs), with results comparable to cervical biopsies.
The Union for International Cancer Control (UICC) invites cities in Asian countries to participate in the global initiative of City Cancer Challenge (CCC) and upgrade their healthcare services for cancer patients.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Oncology - Malaysia digital copy today!
Results of the registrational phase I/II ARROW trial of pralsetinib, presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020, reveal overall response rates (ORRs) of ≥60 percent in pretreated and treatment-naïveRET-mutated (RETmut) medullary thyroid cancer (MTC) patients.